RSV-604

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Investigational

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C22H17FN4O2
Molecular Weight	388.3944
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of RSV-604

Structure Search

SMILES

FC1=CC=CC=C1NC(=O)N[C@H]2N=C(C3=CC=CC=C3)C4=C(NC2=O)C=CC=C4

InChI

InChIKey=MTPVBMVUENFFLL-HXUWFJFHSA-N

InChI=1S/C22H17FN4O2/c23-16-11-5-7-13-18(16)25-22(29)27-20-21(28)24-17-12-6-4-10-15(17)19(26-20)14-8-2-1-3-9-14/h1-13,20H,(H,24,28)(H2,25,27,29)/t20-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C22H17FN4O2
Molecular Weight	388.3944
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Approval Year

Targets

Targets

Primary Target	Pharmacology	Condition	Potency
Respiratory syncytial virus nucleoprotein 1 Target ID: Respiratory syncytial virus nucleoprotein Sources: https://www.ncbi.nlm.nih.gov/pubmed/25451060	Binding Agent 1064

Substance Class	Chemical Created by `admin` on `Sat Dec 16 12:10:21 GMT 2023` Edited by `admin` on `Sat Dec 16 12:10:21 GMT 2023`
Record UNII	6NF9HI6D98
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

RSV-604

Code

English

1-(2-FLUOROPHENYL)-3-((3S)-2-OXO-5-PHENYL-1,3-DIHYDRO-1,4-BENZODIAZEPIN-3-YL)UREA

Systematic Name

English

(S)-N-(2-FLUOROPHENYL)-N'-(2-OXO-5-PHENYL-2,3-DIHYDRO-1H-BENZO(E)(1,4)DIAZEPIN-3-YL)UREA

Systematic Name

English

UREA, N-((3S)-2,3-DIHYDRO-2-OXO-5-PHENYL-1H-1,4-BENZODIAZEPIN-3-YL)-N'-(2-FLUOROPHENYL)-

Systematic Name

English

RSV604

Code

English

RSV 604

Code

English

A-60444

Code

English

Code System Code Type Description

EPA CompTox

DTXSID101125220

Created by admin on Sat Dec 16 12:10:21 GMT 2023 , Edited by admin on Sat Dec 16 12:10:21 GMT 2023

PRIMARY

CLINICAL_TRIALS.GOV

RSV-604

Created by admin on Sat Dec 16 12:10:21 GMT 2023 , Edited by admin on Sat Dec 16 12:10:21 GMT 2023

PRIMARY

Primary Objectives:Pilot Study: A preliminary assessment of the exposure and safety of oral A-60444 in post-stem cell transplant patients with RSV infection.Main Study: To determine the antiviral effect of oral A-60444 versus placebo in post-stem cell transplant patients with RSV infection and to assess the safety of oral A-60444 in post-stem cell transplant patients with RSV infection.Secondary Objectives:To study the pharmacokinetics of A-60444 in the presence of concomitant medications such as immunosuppressants and antifungals, in post-stem cell transplant patients with RSV infection.

PUBCHEM

5279172

Created by admin on Sat Dec 16 12:10:21 GMT 2023 , Edited by admin on Sat Dec 16 12:10:21 GMT 2023

PRIMARY

DRUG BANK

DB15197

Created by admin on Sat Dec 16 12:10:21 GMT 2023 , Edited by admin on Sat Dec 16 12:10:21 GMT 2023

PRIMARY

FDA UNII

6NF9HI6D98

Created by admin on Sat Dec 16 12:10:21 GMT 2023 , Edited by admin on Sat Dec 16 12:10:21 GMT 2023

PRIMARY

SMS_ID

300000041381

Created by admin on Sat Dec 16 12:10:21 GMT 2023 , Edited by admin on Sat Dec 16 12:10:21 GMT 2023

PRIMARY

CAS

676128-63-5

Created by admin on Sat Dec 16 12:10:21 GMT 2023 , Edited by admin on Sat Dec 16 12:10:21 GMT 2023

PRIMARY

Related Record Type Details


					6NF9HI6D98

RSV-604

ACTIVE MOIETY

Comments:

Class: Antiviral, Benzodiazepinone, Phenylurea compound, Small molecule; Mechanism of Action: Nucleocapsid protein inhibitor, Virus replication inhibitor; Highest Development Phase: Discontinued for Respiratory syncytial virus infection; Most Recent Events: 16 Nov 2010 RSV 604 is still in active development, 02 Oct 2008 Preclinical trials in Respiratory syncytial virus infections (in infants) in United Kingdom (PO), 31 Oct 2006 Phase-I clinical trials in Respiratory syncytial virus infections in volunteers United Kingdom (IV)